Elanco Animal Health Gets Its Bite Back, Pipeline Efforts Earn Praise

After years of struggling with market share losses and uneven execution, Elanco Animal Health Incorporated (NYSE:ELAN) appears to be turning a corner.

What Happened: Investor meetings hosted by William Blair this week gave analysts enough confidence to upgrade the stock, citing a stabilized core business and promising momentum in its innovation pipeline. With new product launches in both livestock and pet health, Elanco is better positioned for growth—though it still faces stiff competition from larger rivals like Zoetis and Merck.

Analyst Brandon Vazquez said meetings and conversations centered on current momentum and pipeline efforts, giving the confidence to upgrade.

The analyst highlights that the core business (ex-innovation, or about 85% of sales) has stabilized due to improved execution or, bluntly, years of share losses that have made less competitive segments less impactful ...